Therapeutical Potential And Mechanisms Of Action Of New Compounds From Bitter Melon For Insulin Resistant States
Funder
National Health and Medical Research Council
Funding Amount
$115,155.00
Summary
Type 2 Diabetes is a major disease with major economic and health implications. Current medications are either insufficient or have serious adverse effects. Bitter melon is a vegetable in many countries including Australia and it has been used as a traditional medicine to control blood sugar. This project intends to identify the active ingredients from bitter melon for the treatment of type 2 diabetes. The results will indicate their potential as new agents for this disease.
Investigation Of Novel Triterpenoids As New Potent AMPK Activators For The Treatment Of Insulin Resistant States
Funder
National Health and Medical Research Council
Funding Amount
$574,075.00
Summary
Type 2 Diabetes has major economic and health implications. Current medications are inadequate or have serious adverse effects. Triterpenoids have been used in traditional medicines for various diseases. This project builds on our recent discovery of novel triterpenoids with antidiabetic properties to investigate their efficacy and mechanisms of action. The results will provide valuable information about this class of molecules as potential new therapeutics for Type 2 diabetes.
IGF-1 AS A THERAPEUTIC AGENT: HOW DOES IGF-1 AFFECT OXIDATIVE STRESS IN DYSTROPHIC AND AGED SKELETAL MUSCLE?
Funder
National Health and Medical Research Council
Funding Amount
$545,243.00
Summary
Loss of skeletal muscle mass (wasting) and function occurs in many clinical conditions, including muscular dystrophy, neuromuscular and inflammatory disorders, and also normal ageing. A growth factor (IGF-1) is a promising therapeutic as it increases protein synthesis. Muscle wasting (loss of protein) is also associated with increased oxidative stress. The project will evaluate the impact of IGF-1 on oxidative stress using genetically engineered mouse models of muscular dystrophy and ageing.
Clarifying Molecular Role Of IGF-1:Ea Isoforms In Skeletal Muscle Hypertrophy And Atrophy
Funder
National Health and Medical Research Council
Funding Amount
$394,718.00
Summary
The growth factor IGF-1 is proposed as a therapeutic agent to increase muscle mass and to reduce muscle wasting resulting from denervation, disuse, ageing and dystrophy. Understanding the precise mechanisms of IGF-1 action is essential for the potential therapeutic use of this factor. This research is focused on the molecular role of IGF-1 in healthy muscle and in the conditions of muscle wasting and degeneration.